Phathom Pharmaceuticals Posts Strong Revenue Growth but Faces Profitability Timelines
Event summary
- Phathom reported $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024.
- Q4 2025 net revenues were $57.6 million, up $27.9 million year-over-year.
- Over 1.1 million VOQUEZNA prescriptions filled as of February 13, 2026.
- Completed a $130 million equity offering and modified term debt in early 2026.
- Expects operating profitability beginning Q3 2026.
The big picture
Phathom's strong revenue growth reflects successful commercialization of VOQUEZNA, but its path to profitability hinges on disciplined expense management and sustained prescription momentum. The company's strategic financial moves—including debt modification and equity offering—aim to bolster liquidity as it navigates the competitive gastrointestinal therapeutics market.
What we're watching
- Commercial Execution
- Whether Phathom can sustain prescription growth through its realigned sales force and marketing initiatives.
- Profitability Timelines
- The pace at which the company achieves operating profitability in Q3 2026, as guided.
- Clinical Development
- Topline results from the Phase 2 pHalcon-EoE-201 trial for Eosinophilic Esophagitis, expected in 2027.
Related topics